Andrea Morotti1,2, H Bart Brouwers3, Javier M Romero2,4, Michael J Jessel2, Anastasia Vashkevich2, Kristin Schwab2, Mohammad Rauf Afzal5, Christy Cassarly6, Steven M Greenberg2, Renee Hebert Martin6, Adnan I Qureshi5, Jonathan Rosand1,2, Joshua N Goldstein1,2,7. 1. Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston. 2. J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston. 3. Department of Neurosurgery, Brain Center Rudolf Magnus University Medical Center, Utrecht, the Netherlands. 4. Neuroradiology Service, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston. 5. Zeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis. 6. Department of Public Health Sciences, Medical University of South Carolina, Charleston. 7. Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Abstract
Importance: The computed tomographic angiography (CTA) spot sign is associated with intracerebral hemorrhage (ICH) expansion and may mark those patients most likely to benefit from intensive blood pressure (BP) reduction. Objective: To investigate whether the spot sign is associated with ICH expansion across a wide range of centers and whether intensive BP reduction decreases hematoma expansion and improves outcome in patients with ICH and a spot sign. Design, Setting, and Participants: SCORE-IT (Spot Sign Score in Restricting ICH Growth) is a preplanned prospective observational study nested in the Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH-II) randomized clinical trial. Participants included consecutive patients with primary ICH who underwent a CTA within 8 hours from onset at 59 sites from May 15, 2011, through December 19, 2015. Data were analyzed for the present study from July 1 to August 31, 2016. Main Outcomes and Measures: Patients in ATACH-II were randomized to intensive (systolic BP target, <140 mm Hg) vs standard (systolic BP target, <180 mm Hg) BP reduction within 4.5 hours from onset. Expansion of ICH was defined as hematoma growth of greater than 33%, and an unfavorable outcome was defined as a 90-day modified Rankin Scale score of 4 or greater (range, 0-6). The association among BP reduction, ICH expansion, and outcome was investigated with multivariable logistic regression. Results: A total of 133 patients (83 men [62.4%] and 50 women [37.6%]; mean [SD] age, 61.9 [13.1] years) were included. Of these, 53 (39.8%) had a spot sign, and 24 of 123 without missing data (19.5%) experienced ICH expansion. The spot sign was associated with expansion with sensitivity of 0.54 (95% CI, 0.34-0.74) and specificity of 0.63 (95% CI, 0.53-0.72). After adjustment for potential confounders, intensive BP treatment was not associated with a significant reduction of ICH expansion (relative risk, 0.83; 95% CI, 0.27-2.51; P = .74) or improved outcome (relative risk of 90-day modified Rankin Scale score ≥4, 1.24; 95% CI, 0.53-2.91; P = .62) in spot sign-positive patients. Conclusions and Relevance: The predictive performance of the spot sign for ICH expansion was lower than in prior reports from single-center studies. No evidence suggested that patients with ICH and a spot sign specifically benefit from intensive BP reduction. Trial Registration: clinicaltrials.gov Identifier: NCT01176565.
RCT Entities:
Importance: The computed tomographic angiography (CTA) spot sign is associated with intracerebral hemorrhage (ICH) expansion and may mark those patients most likely to benefit from intensive blood pressure (BP) reduction. Objective: To investigate whether the spot sign is associated with ICH expansion across a wide range of centers and whether intensive BP reduction decreases hematoma expansion and improves outcome in patients with ICH and a spot sign. Design, Setting, and Participants: SCORE-IT (Spot Sign Score in Restricting ICH Growth) is a preplanned prospective observational study nested in the Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH-II) randomized clinical trial. Participants included consecutive patients with primary ICH who underwent a CTA within 8 hours from onset at 59 sites from May 15, 2011, through December 19, 2015. Data were analyzed for the present study from July 1 to August 31, 2016. Main Outcomes and Measures: Patients in ATACH-II were randomized to intensive (systolic BP target, <140 mm Hg) vs standard (systolic BP target, <180 mm Hg) BP reduction within 4.5 hours from onset. Expansion of ICH was defined as hematoma growth of greater than 33%, and an unfavorable outcome was defined as a 90-day modified Rankin Scale score of 4 or greater (range, 0-6). The association among BP reduction, ICH expansion, and outcome was investigated with multivariable logistic regression. Results: A total of 133 patients (83 men [62.4%] and 50 women [37.6%]; mean [SD] age, 61.9 [13.1] years) were included. Of these, 53 (39.8%) had a spot sign, and 24 of 123 without missing data (19.5%) experienced ICH expansion. The spot sign was associated with expansion with sensitivity of 0.54 (95% CI, 0.34-0.74) and specificity of 0.63 (95% CI, 0.53-0.72). After adjustment for potential confounders, intensive BP treatment was not associated with a significant reduction of ICH expansion (relative risk, 0.83; 95% CI, 0.27-2.51; P = .74) or improved outcome (relative risk of 90-day modified Rankin Scale score ≥4, 1.24; 95% CI, 0.53-2.91; P = .62) in spot sign-positive patients. Conclusions and Relevance: The predictive performance of the spot sign for ICH expansion was lower than in prior reports from single-center studies. No evidence suggested that patients with ICH and a spot sign specifically benefit from intensive BP reduction. Trial Registration: clinicaltrials.gov Identifier: NCT01176565.
Authors: Gregoire Boulouis; Andrea Morotti; H Bart Brouwers; Andreas Charidimou; Michael J Jessel; Eitan Auriel; Octávio Pontes-Neto; Alison Ayres; Anastasia Vashkevich; Kristin M Schwab; Jonathan Rosand; Anand Viswanathan; Mahmut E Gurol; Steven M Greenberg; Joshua N Goldstein Journal: JAMA Neurol Date: 2016-08-01 Impact factor: 18.302
Authors: H Bart Brouwers; Guido J Falcone; Kristen A McNamara; Alison M Ayres; Alexandra Oleinik; Kristin Schwab; Javier M Romero; Anand Viswanathan; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein Journal: Neurocrit Care Date: 2012-12 Impact factor: 3.210
Authors: A Morotti; J M Romero; M J Jessel; H B Brouwers; R Gupta; K Schwab; A Vashkevich; A Ayres; C D Anderson; M E Gurol; A Viswanathan; S M Greenberg; J Rosand; J N Goldstein Journal: AJNR Am J Neuroradiol Date: 2016-05-19 Impact factor: 3.825
Authors: Charlotte Jj van Asch; Merel Ja Luitse; Gabriël Je Rinkel; Ingeborg van der Tweel; Ale Algra; Catharina Jm Klijn Journal: Lancet Neurol Date: 2010-01-05 Impact factor: 44.182
Authors: Josser E Delgado Almandoz; Albert J Yoo; Michael J Stone; Pamela W Schaefer; Joshua N Goldstein; Jonathan Rosand; Alexandra Oleinik; Michael H Lev; R Gilberto Gonzalez; Javier M Romero Journal: Stroke Date: 2009-07-02 Impact factor: 7.914
Authors: Dar Dowlatshahi; H Bart Brouwers; Andrew M Demchuk; Michael D Hill; Richard I Aviv; Lee-Anne Ufholz; Michael Reaume; Max Wintermark; J Claude Hemphill; Yasuo Murai; Yongjun Wang; Xingquan Zhao; Yilong Wang; Na Li; Takatoshi Sorimachi; Mitsunori Matsumae; Thorsten Steiner; Timolaos Rizos; Steven M Greenberg; Javier M Romero; Jonathan Rosand; Joshua N Goldstein; Mukul Sharma Journal: Stroke Date: 2016-02-04 Impact factor: 7.914
Authors: Andrea Morotti; Dar Dowlatshahi; Gregoire Boulouis; Fahad Al-Ajlan; Andrew M Demchuk; Richard I Aviv; Liyang Yu; Kristin Schwab; Javier M Romero; M Edip Gurol; Anand Viswanathan; Christopher D Anderson; Yuchiao Chang; Steven M Greenberg; Adnan I Qureshi; Jonathan Rosand; Joshua N Goldstein Journal: Stroke Date: 2018-04-18 Impact factor: 7.914
Authors: Frieder Schlunk; Maximilian Böhm; Gregoire Boulouis; Tao Qin; Michal Arbel; Isra Tamim; Paul Fischer; Brian J Bacskai; Matthew P Frosch; Matthias Endres; Steven M Greenberg; Cenk Ayata Journal: Stroke Date: 2019-05 Impact factor: 7.914
Authors: Andrea Morotti; Gregoire Boulouis; Andreas Charidimou; Kristin Schwab; Christina Kourkoulis; Christopher D Anderson; M Edip Gurol; Anand Viswanathan; Javier M Romero; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein Journal: Stroke Date: 2018-09 Impact factor: 7.914